News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
542,054 Results
Type
Article (13912)
Company Profile (191)
Press Release (527948)
Multimedia
Podcasts (100)
Webinars (17)
Section
Business (183690)
Career Advice (654)
Deals (28534)
Drug Delivery (51)
Drug Development (63194)
Employer Resources (81)
FDA (10758)
Job Trends (10080)
News (266627)
Policy (20632)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (4)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (4)
Academia (685)
Accelerated approval (37)
ADA (24)
Adcomms (5)
Allergies (125)
Alliances (37356)
ALS (155)
Alzheimer's disease (1212)
Antibody-drug conjugate (ADC) (447)
Approvals (11430)
Artificial intelligence (536)
ASCO (222)
Autoimmune disease (280)
Automation (45)
Bankruptcy (281)
Belgium (7)
Best Places to Work (7722)
BIO (57)
Biologics (21)
BIOSECURE Act (16)
Biosimilars (194)
BioSpace Insights (71)
Biotechnology (121)
Bispecific (4)
Bladder cancer (158)
Brain cancer (49)
Breast cancer (572)
Cancer (4707)
Cardiovascular disease (298)
Career advice (595)
Career pathing (45)
CAR-T (249)
CDC (16)
CDMO (99)
Celiac Disease (2)
Cell-line development (1)
Cell therapy (662)
Cervical cancer (40)
Clinical research (57419)
Collaboration (1712)
Commercialization (14)
Company closure (1)
Compensation (1686)
Complete response letters (60)
COVID-19 (1169)
CRISPR (72)
C-suite (1113)
Cystic fibrosis (105)
Data (7119)
Decentralized trials (1)
Denatured (18)
Depression (137)
Dermatology (93)
Diabetes (433)
Diagnostics (4520)
Digital health (45)
Diversity (7)
Diversity, equity & inclusion (19)
Drug discovery (242)
Drug pricing (70)
Drug shortages (5)
Duchenne muscular dystrophy (201)
Earnings (78940)
Editorial (52)
Employer branding (12)
Employer resources (73)
Events (97939)
Executive appointments (954)
FDA (14055)
Fibrodysplasia Ossificans Progressiva (11)
Friedreich's ataxia (22)
Frontotemporal dementia (29)
Funding (1310)
Gene editing (149)
Generative AI (31)
Gene therapy (467)
GLP-1 (547)
Government (1521)
Grass and pollen (3)
Guidances (328)
Healthcare (10245)
Hematology (130)
HIV (67)
Huntington's disease (34)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (82)
Immunology and inflammation (193)
Immuno-oncology (100)
Indications (198)
Infectious disease (1406)
Inflammatory bowel disease (170)
Inflation Reduction Act (11)
Influenza (99)
Intellectual property (301)
Interviews (107)
IPO (13825)
IRA (19)
Job creations (2548)
Job search strategy (477)
JPM (36)
Kidney cancer (21)
Kidney disease (60)
Labor market (113)
Layoffs (253)
Leadership (45)
Legal (5540)
Licensing (30)
Liver cancer (67)
Longevity (23)
Lung cancer (734)
Lung diease (12)
Lymphoma (331)
Machine learning (44)
Management (27)
Manufacturing (885)
Marketing (13)
MASH (185)
Medical affairs (2)
Medical device (8873)
Medtech (9038)
Mergers & acquisitions (15939)
Metabolic disorders (1040)
mRNA (127)
Multiple sclerosis (156)
NASH (8)
Netherlands (3)
Neurodegenerative disease (321)
Neuropsychiatric disorders (71)
Neuroscience (2429)
NextGen: Class of 2026 (3576)
Non-profit (997)
Now hiring (76)
Obesity (391)
Opinion (147)
Ovarian cancer (186)
Pain (207)
Pancreatic cancer (254)
Parkinson's disease (274)
Partnered (16)
Patents (580)
Patient advocacy (1)
Patient recruitment (673)
Patient selection (19)
Peanut (48)
People (46544)
Peptides (5)
Pharmaceutical (45)
Pharmacy benefit managers (11)
Phase 1 (18316)
Phase 2 (25793)
Phase 3 (17836)
Pipeline (9381)
Policy (170)
Postmarket research (1719)
Preclinical (7521)
Press Release (45)
Prostate cancer (234)
Psychedelics (30)
Radiopharmaceuticals (294)
Rare diseases (833)
Real estate (3663)
Recruiting (37)
Regenerative medicine (8)
Regulatory (17844)
Reports (52)
Research institute (767)
Resumes & cover letters (86)
Rett syndrome (44)
RNA editing (10)
RSV (56)
Schizophrenia (157)
Series A (233)
Series B (166)
Service/supplier (6)
Sickle cell disease (74)
Special edition (28)
Spinal muscular atrophy (103)
Sponsored (13)
Startups (2495)
State (1)
Stomach cancer (5)
Substance use disorders (17)
Supply chain (72)
Tariffs (49)
The Weekly (81)
Vaccines (515)
Venture capital (85)
Weight loss (179)
Wet AMD (1)
Women's health (106)
Worklife (20)
Date
Today (30)
Last 7 days (429)
Last 30 days (1796)
Last 365 days (23023)
2026 (17292)
2025 (22857)
2024 (26722)
2023 (30799)
2022 (39013)
2021 (41854)
2020 (37477)
2019 (26765)
2018 (20198)
2017 (21943)
2016 (20836)
2015 (27081)
2014 (23806)
2013 (19762)
2012 (21565)
2011 (21801)
2010 (21551)
Location
Africa (357)
Alabama (95)
Alaska (2)
Arizona (346)
Arkansas (13)
Asia (26635)
Australia (3208)
California (13485)
Canada (3431)
China (1316)
Colorado (532)
Connecticut (512)
Delaware (345)
Europe (43434)
Florida (2024)
Georgia (411)
Hawaii (3)
Idaho (46)
Illinois (851)
India (82)
Indiana (412)
Iowa (21)
Japan (578)
Kansas (115)
Kentucky (36)
Louisiana (30)
Maine (28)
Maryland (1423)
Massachusetts (9254)
Michigan (324)
Minnesota (614)
Mississippi (5)
Missouri (91)
Montana (20)
Nebraska (13)
Nevada (126)
New Hampshire (67)
New Jersey (3245)
New Mexico (15)
New York (3394)
North Carolina (1579)
North Dakota (4)
Northern California (6843)
Ohio (326)
Oklahoma (19)
Oregon (28)
Pennsylvania (2492)
Puerto Rico (30)
Rhode Island (34)
South America (552)
South Carolina (79)
South Dakota (1)
Southern California (5533)
Tennessee (130)
Texas (2176)
United States (44885)
Utah (399)
Vermont (1)
Virginia (187)
Washington D.C. (50)
Washington State (1056)
West Virginia (2)
Wisconsin (92)
Wyoming (1)
542,054 Results for "akeso biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
September 3, 2026
·
2 min read
·
Annalee Armstrong
China
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
Ivonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines over time.
August 17, 2026
·
2 min read
·
Annalee Armstrong
Immuno-oncology
ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.
May 31, 2026
·
3 min read
·
Annalee Armstrong
Cancer
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.
August 26, 2026
·
2 min read
·
Heather McKenzie
Lung cancer
Summit and Akeso sharpen case for ivonescimab with new Western data
Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.
July 22, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
September 13, 2026
·
15 min read
Press Releases
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
September 28, 2026
·
12 min read
Press Releases
Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
September 17, 2026
·
6 min read
Press Releases
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
September 22, 2026
·
6 min read
China
Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector
From a small team of researchers and skipped salaries, CEO Michelle Xia has steered Akeso to become one of the most exciting companies in the industry today.
September 17, 2025
·
8 min read
·
Tristan Manalac
1 of 54,206
Next